Trials / Recruiting
RecruitingNCT07380711
Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes
Prospective and Retrospective Observational Real-world Study to Characterize Patients With COPD on Dupilumab Long-term Treatment, and Assess Safety and Patient Reported Outcomes
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The OBS19236 is a retrospective and prospective, non-interventional observational study in COPD patients treated with dupilumab as part of routine clinical care. It will follow-up about 350 to 500 participants over 36 months in up to 50 sites in France.
Detailed description
Study duration per participant is expected to be approximately 36 months.
Conditions
Timeline
- Start date
- 2026-01-28
- Primary completion
- 2030-08-14
- Completion
- 2030-08-14
- First posted
- 2026-02-02
- Last updated
- 2026-04-14
Locations
22 sites across 1 country: France
Source: ClinicalTrials.gov record NCT07380711. Inclusion in this directory is not an endorsement.